Bio-Techne Corporation and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), will be shortly be launching the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support the rapid distribution of the assay to the vaccine development community.  The COVID-SeroIndex test kit is expected to be available for research use in early August.  

The COVID-SeroIndex test kit is an ELISA assay, designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer (level) of antibodies a person has produced.  It utilizes not one, but two virus antigens: the full-length spike protein, and its receptor binding domain. The underlying technology was created by Mount Sinai's internationally recognized team of virologists and pathologists and has been tested on over 50,000 patient samples.

"The launch of a RUO version of the COVID-19 serology test brings to the research community what we believe is the highest quality SARS-CoV-2 antibody assay available," commented Dave Eansor, Bio-Techne's Protein Sciences Segment President.  "The assay supports the life cycle of COVID-19 vaccine development, providing researchers with an objective way of measuring antibody titer."